Biotech Drug Report Generated Nov 5, 2026

Dazodalibep

AMGN·Amgen

NEUTRAL

Drug Impact Rating5/10

Trial Phase: Phase 3
Time to Market: If OASIZ 303 reads out positively by end of 2026 and Amgen files a BLA shortly after, FDA review would take roughly 10-12 months, suggesting a potential approval decision in late 2027 or early 2028 at the earliest.
Why 5/10: The next hard, dated catalyst is the OASIZ 303 Phase 3 topline readout expected to complete in Q4 2026 (by end of December 2026). However, dazodalibep is one of many pipeline assets at Amgen, a mega-cap biotech (~$130B+ market cap), and the OASIZ 301 already succeeded, reducing the binary nature of the OASIZ 303 readout. Impact score is 5.

Actionable Insight NEUTRAL

The next catalyst is the OASIZ 303 Phase 3 topline readout, expected by end of Q4 2026 (any day now). A positive result would validate dazodalibep across both Sjögren's subpopulations (systemic and symptomatic), strengthening the case for a BLA filing. A negative or mixed readout would not kill the program (OASIZ 301 already succeeded) but would narrow the addressable label. Amgen has not yet disclosed a regulatory submission timeline; watch for that announcement after OASIZ 303 data.

Price Chart

Loading chart...

Executive Summary

Dazodalibep is a CD40L antagonist fusion protein being developed by Amgen (NASDAQ: AMGN) for Sjögren's disease, a chronic autoimmune condition with no FDA-approved disease-modifying therapies. In September 2026, Amgen announced positive Phase 3 topline results from the OASIZ 301 trial, which met its primary endpoint of improving systemic disease activity (ESSDAI score) at Week 48. The drug originated from AstraZeneca/MedImmune and came to Amgen through its $27.8 billion acquisition of Horizon Therapeutics (which had acquired Viela Bio for $3 billion in 2021). A second Phase 3 trial (OASIZ 303) in patients with high symptom burden but low systemic disease activity is expected to complete in Q4 2026. Amgen has not yet disclosed a regulatory filing timeline. Dazodalibep is also being investigated in a Phase 2a lupus nephritis trial. For a mega-cap company like Amgen, dazodalibep is one of many pipeline assets, and the stock's reaction to the OASIZ 301 win was muted.

How It Works

Dazodalibep is a lab-engineered fusion protein that acts as a CD40 ligand (CD40L) antagonist. In simple terms, it blocks a key communication signal between immune cells (T cells, B cells, and antigen-presenting cells). By disrupting this signal, the drug aims to tamp down the overactive immune response that drives autoimmune diseases like Sjögren's disease. It uses a special 'Fc-silent' design intended to avoid the blood-clot risks that plagued earlier drugs targeting the same pathway.

Trial Status

Phase 3 OASIZ 301 (systemic Sjögren's, n=651) completed and met its primary endpoint with positive topline results announced September 22, 2026. Phase 3 OASIZ 303 (symptomatic Sjögren's, low systemic activity) is expected to complete in Q4 2026. A long-term extension study (OASIZ 304) is enrolling. Phase 2a trial in lupus nephritis is recruiting. Phase 2 MIDORA trial in rheumatoid arthritis has been completed. Development in focal segmental glomerulosclerosis and renal transplant rejection has been discontinued.

The Two-Sided Case

▲ Bull Case5

Dazodalibep met its Phase 3 OASIZ 301 primary endpoint (ESSDAI improvement at Week 48) with statistical significance, in a disease with zero FDA-approved disease-modifying therapies -- a large, clear unmet need.

The drug is a potential first-in-class CD40L antagonist fusion protein with a novel Fc-silent design that may avoid the thromboembolic risks that doomed earlier CD40L-targeting drugs.

Amgen is also studying dazodalibep in lupus nephritis (Phase 2a), expanding the addressable market beyond Sjögren's disease.

The Sjögren's syndrome treatment market is estimated at $266M-$620M in 2026 and projected to grow at 3-6% CAGR, with no approved DMTs -- dazodalibep could capture significant share if approved.

Multiple analysts raised price targets on AMGN in early November 2026 (UBS to $530, Scotiabank to $530, TD Cowen to $531), partly reflecting pipeline progress including dazodalibep.

▼ Bear Case5

Amgen has not disclosed the effect size or p-value from OASIZ 301, only that the result was 'statistically significant and clinically meaningful' -- the magnitude matters for commercial potential.

OASIZ 303 targets a distinct Sjögren's population (high symptom burden, low systemic activity), and Amgen has cautioned that the systemic OASIZ 301 success may not read through to the symptomatic population.

Dazodalibep is one of many pipeline assets at a mega-cap company (~$130B+ market cap); even a blockbuster Sjögren's drug would move the stock only modestly.

The drug has changed corporate hands three times (AstraZeneca/Viela/Horizon/Amgen), and earlier CD40L-targeting therapies faced blood-clot safety issues, though dazodalibep uses an Fc-silent design to mitigate that risk.

Analyst consensus on AMGN is mixed (12 Buy, 20 Hold, 3 Sell, 6 Strong Buy, 1 Strong Sell) with a mean price target of $404 vs the current ~$479 price, implying -15.5% downside.

Upcoming Catalysts

OASIZ 303 Phase 3 topline readout expected by end of Q4 2026 (any day now)
Detailed OASIZ 301 data presentation at an upcoming medical meeting
Potential BLA filing announcement if OASIZ 303 also succeeds
Phase 2a lupus nephritis data readout (timeline undisclosed)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Amgen PRESS-RELEASE AMGN ·Originating report

Sources · 13

Hover a chip for the title

1 amgen.com2 allsci.com3 fiercebiotech.com4 nature.com5 adis.springer.com6 peptideandprotein.com7 biospace.com8 sjogrens.org9 novapharmanews.com10 amgen.com11 ainvest.com12 hss.edu13 clinicaltrials.gov